Both methimazole and propylthiouracil (PTU) inhibit TPO, however methimazole does not effectively block peripheral deiodinase D1 that converts T4 to T3, in contrast to PTU that inhibits both TPO and deiodinase D1

Disclosures: Oluwaseun Falade-Nwulia: AbbVie Inc: Grant/Research Support, Gilead Sciences: Advisor, Jennifer Price: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Ellen Eaton: Gilead Foundation: Patient Engagement Working Group, Franco Ricardo: Nothing to Disclose, Brittany Barnaba: Pfizer, Inc.: Stock - publicly traded company, Diane Brown: Nothing to Disclose, Sarah Hussain: Nothing to Disclose, Catherine Wren: Nothing to Disclose, Hamidreza Karimi Sari: Nothing to Disclose, Kyoko Hirose: Nothing to Disclose, Chris Cavacuiti: Nothing to Disclose, Stephen O'rear: Nothing to Disclose, Camelia Capraru: Nothing to Disclose, Karin Tobin: Nothing to Disclose, Sheree Schwartz: Nothing to Disclose, Mark Sulkowski: Nothing to Disclose 705 REGNASE-1 DOWN-REGULATION CONTRIBUTES TO MYELOID CELL INTERMEDIATED ICC DEVELOPMENT Yu Sato 1 Takahiro Kodama 1 Yoshinobu Saito 1 Yuki Tahata 1 Kazuhiro Murai 1 Akira Doi 1 Kumiko Shirai 1 Kazuki Maesaka 1 Hayato Hikita 1 Tomohide Tatsumi 1 Tetsuo Takehara 1 , 1 Osaka University Background: The tumor immune microenvironment (TIME) is a therapeutic target for primary liver cancers

What would LDs do if embryos were in an environment filled with bacterial contamination
Thus, OIC was successfully established by Loperamide administration
The specific risks typically vary with the materials used